Seoul, South Korea

Min Suk Lee



Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Min Suk Lee - Innovator in Human Growth Hormone Formulation

Introduction

Min Suk Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of human growth hormone. His innovative work has led to the development of a stable liquid formulation that enhances the efficacy of this important hormone.

Latest Patents

Min Suk Lee holds 1 patent for his invention titled "Stable liquid formulation of human growth hormone." This patent discloses a stable liquid formulation comprising human growth hormone, L-lysine, L-arginine or polyethylene glycol 300, and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate, or polyethylene glycol-35 castor oil. This formulation is designed to improve the stability and delivery of human growth hormone, making it more effective for therapeutic use.

Career Highlights

Min Suk Lee is associated with Daewoong Co., Ltd., a leading pharmaceutical company in South Korea. His work at Daewoong has been instrumental in advancing the company's research and development efforts in hormone therapies. His innovative approach and dedication to improving patient outcomes have earned him recognition in the industry.

Collaborations

Min Suk Lee collaborates with talented professionals in his field, including Sun Hee Kim and Yo Kyung Chung. These collaborations have fostered a creative environment that encourages the exchange of ideas and the development of groundbreaking solutions in pharmaceutical formulations.

Conclusion

Min Suk Lee's contributions to the field of human growth hormone formulation exemplify the impact of innovation in pharmaceuticals. His work not only advances scientific knowledge but also enhances the quality of life for patients requiring hormone therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…